A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into "Low-" and "High-Risk" Categories for Prostate Cancer.
EGF
IL-8
MCP-1
algorithm
fPSA
marker
prostate cancer
tPSA
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
14
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies. Serum samples and clinical information were collected from The data showed that 11/19 (68.8%) markers were significantly different between the non-PCa and the PCa patients. A combination of EGF, log The novel combination of serum markers identified in this study could be employed to help triage patients into "low-" and "high-risk" categories, allowing general practitioners to improve the management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.
Sections du résumé
Background
UNASSIGNED
Almost 50,000 men in the United Kingdom (UK) are diagnosed each year with prostate cancer (PCa). Secondary referrals for investigations rely on serum prostate-specific antigen (PSA) levels and digital rectal examination. However, both tests lack sensitivity and specificity, resulting in unnecessary referrals to secondary care for costly and invasive biopsies.
Materials and Methods
UNASSIGNED
Serum samples and clinical information were collected from
Results
UNASSIGNED
The data showed that 11/19 (68.8%) markers were significantly different between the non-PCa and the PCa patients. A combination of EGF, log
Conclusions
UNASSIGNED
The novel combination of serum markers identified in this study could be employed to help triage patients into "low-" and "high-risk" categories, allowing general practitioners to improve the management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.
Identifiants
pubmed: 35664747
doi: 10.3389/fonc.2022.837127
pmc: PMC9161691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
837127Informations de copyright
Copyright © 2022 McNally, Watt, Kurth, Lamont, Moore, Fitzgerald, Pandha, McKenna and Ruddock.
Déclaration de conflit d'intérêts
The authors declare that this study received funding from Randox Laboratories Ltd as part of the Randox Laboratories Ltd – Ulster University PhD Academy Studentship. Randox had the following involvement in the study: analysis of patient samples, statistical analysis, supervision of the project, preparation of the manuscript, and the decision to publish. JW, MJK, JL, and MR are employees of Randox Laboratories Ltd. but hold no shares in the company. PF is the managing director and owner of Randox Laboratories Ltd. A patent has been filed to protect the biomarker combination disclosed in the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Investig J. 2014;3(1):72-79
pubmed: 25593898
Anticancer Res. 2017 Feb;37(2):413-424
pubmed: 28179286
Med Care. 2013 Apr;51(4):295-300
pubmed: 23269114
Radiat Oncol. 2013 Apr 25;8:100
pubmed: 23618468
Mod Pathol. 2018 Jan;31(S1):S47-63
pubmed: 29297487
Haematologica. 2012 Aug;97(8):1158-64
pubmed: 22371182
Eur Urol. 2013 Mar;63(3):428-35
pubmed: 23084329
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):129-35
pubmed: 21339768
Transl Cancer Res. 2019 Feb;8(1):273-278
pubmed: 35116756
Sci Rep. 2020 Nov 17;10(1):20005
pubmed: 33203963
Rev Urol. 2015;17(1):3-13
pubmed: 26028995
J Urol. 2000 Jul;164(1):214-8
pubmed: 10840462
Am J Surg Pathol. 2000 Dec;24(12):1634-40
pubmed: 11117784
Int J Biol Markers. 2018 Jan;33(1):10-21
pubmed: 28885659
Sci Rep. 2021 Jan 28;11(1):2525
pubmed: 33510263
J Natl Cancer Inst. 2006 Apr 19;98(8):529-34
pubmed: 16622122
N Engl J Med. 2009 Mar 26;360(13):1320-8
pubmed: 19297566
Cancer Manag Res. 2020 Jul 01;12:5225-5241
pubmed: 32669872
Neoplasia. 2006 Jul;8(7):578-86
pubmed: 16867220
Prostate. 2006 Sep 1;66(12):1311-8
pubmed: 16705739
Thromb Haemost. 2005 May;93(5):964-75
pubmed: 15886816
Can J Urol. 2012 Dec;19(6):6542-7
pubmed: 23228289
Clin Chem. 2005 Jul;51(7):1165-76
pubmed: 15890889
Future Sci OA. 2017 Nov 15;4(2):FSO266
pubmed: 29379640
Eur Urol. 2003 Sep;44(3):309-14; discussion 314
pubmed: 12932928
Clin Chem Lab Med. 2020 Feb 25;58(3):326-339
pubmed: 31714881
Sci Rep. 2019 Nov 19;9(1):17119
pubmed: 31745217
Br J Cancer. 2019 May;120(11):1045-1051
pubmed: 31015558
BMJ. 2009 Sep 24;339:b3601
pubmed: 19778971
Prostate Int. 2017 Sep;5(3):110-112
pubmed: 28828354
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Expert Rev Anticancer Ther. 2016;16(4):433-40
pubmed: 27008205
Int J Urol. 2015 Jun;22(6):524-32
pubmed: 25847604
Can Fam Physician. 2015 Jan;61(1):33-9
pubmed: 25756141
BMC Med Inform Decis Mak. 2020 Jul 3;20(1):148
pubmed: 32620120
Rev Urol. 2006;8 Suppl 2:S56-67
pubmed: 17021643
Eur Urol Focus. 2018 Sep;4(5):707-710
pubmed: 28753803
Prostate. 2019 May;79(7):732-745
pubmed: 30900284
Br J Gen Pract. 2006 Oct;56(531):756-62
pubmed: 17007705
Arch Ital Urol Androl. 2021 Mar 22;93(1):92-100
pubmed: 33754619